Back to top
more

BioRad Laboratories (BIO)

(Real Time Quote from BATS)

$265.11 USD

265.11
138,305

-7.07 (-2.60%)

Updated Aug 6, 2025 01:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

QIAGEN's QFT-Plus Approval in Japan to Expand Customer Base

by Zacks Equity Research

QIAGEN (QGEN) continues to strengthen Molecular Diagnostics business with focus on expanding QuantiFERON-TB Gold Plus customer base.

    Zacks Equity Research

    QIAGEN Strong on Molecular Diagnostics, Competition Rife

    by Zacks Equity Research

    QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and declining HPV sales.

      Zacks Equity Research

      Illumina Banks on Strategic Partnerships, Competition Rife

      by Zacks Equity Research

      Illumina's (ILMN) recently-signed partnership to distribute Thermo Fisher's Ion AmpliSeq technology is encouraging.

        Zacks Equity Research

        Align Technology Banks on Global Growth, Competition Rife

        by Zacks Equity Research

        We are encouraged by Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally, particularly in Asia Pacific.

          Zacks Equity Research

          Genomic Health (GHDX) Oncotype DX GPS Test Results Positive

          by Zacks Equity Research

          Genomic Health's (GHDX) efforts to improve its prostate cancer business are encouraging.

            Zacks Equity Research

            What's in Store for GNC Holdings (GNC) This Earnings Season?

            by Zacks Equity Research

            GNC Holdings (GNC) likely to see decline in year-over-year revenues owing to weakness in U.S. & Canada segment in Q4.

              Zacks Equity Research

              Cardiovascular Systems' Micro Crown Now Available in Japan

              by Zacks Equity Research

              Cardiovascular Systems (CSII) is positioned to gain from favorable trend in the CAD market.

                Zacks Equity Research

                Integra LifeSciences Global Prospects Solid, Competition Rife

                by Zacks Equity Research

                Integra LifeSciences (IART) witnesses strong global sales within specialty surgical driven by strength in door repair and tissue ablation franchises in Asia Pacific and Europe.

                  Zacks Equity Research

                  Will Covance Drug Development Drive LabCorp (LH) Q4 Earnings?

                  by Zacks Equity Research

                  LabCorp (LH) is expected to gain from LabCorp Diagnostics and Covance Drug Development segments in Q4.

                    Zacks Equity Research

                    Veeva Systems' Product Portfolio Strong, Competition Rife

                    by Zacks Equity Research

                    Veeva Systems (VEEV) rides on growing demand for cloud-based and vault applications. However, the company faces cutthroat competition in the niche space.

                      Zacks Equity Research

                      Abaxis (ABAX) at a 52-Week High: What's Driving the Stock?

                      by Zacks Equity Research

                      Abaxis (ABAX) rides high on recently received approval from USDA.

                        Zacks Equity Research

                        Intuitive Surgical Gains on FDA Approvals, Competition Rife

                        by Zacks Equity Research

                        Intuitive Surgical (ISRG) gains significantly on CE Mark approval for da Vinci X in Europe.

                          Zacks Equity Research

                          AngioDynamics Receives FDA Nod, to Treat Pancreatic Cancer

                          by Zacks Equity Research

                          AngioDynamics (ANGO) gets flagship NanoKnife designated with EAP.

                            Zacks Equity Research

                            Intuitive Surgical (ISRG) Beats on Q4 Earnings & Revenues

                            by Zacks Equity Research

                            Intuitive Surgical (ISRG) gains from revenue growth in Instrument & Accessories plus Services and Systems segments in Q4.

                              Zacks Equity Research

                              PerkinElmer (PKI) Beats on Q4 Earnings, Issues 2018 Guidance

                              by Zacks Equity Research

                              Solid performance in Discovery & Analytical Solutions segment drives PerkinElmer (PKI) in Q4. A strong guidance for FY18 instills investor's optimism.

                                Zacks Equity Research

                                Varian Medical (VAR) Beats Q1 Earnings & Revenue Estimates

                                by Zacks Equity Research

                                HyperArc and Halcyon platforms drive Varian Medical's (VAR) Q1 results.

                                  Zacks Equity Research

                                  Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?

                                  by Zacks Equity Research

                                  Myriad (MYGN) positioned to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight and EndoPredict tests.

                                    Zacks Equity Research

                                    Is AmerisourceBergen (ABC) Poised for a Beat in Q1 Earnings?

                                    by Zacks Equity Research

                                    AmerisourceBergen's (ABC) Q1 results are expected to gain on strength in pharmaceutical distribution segment.

                                      Zacks Equity Research

                                      Mckesson (MCK) to Report Q3 Earnings: A Beat in the Cards?

                                      by Zacks Equity Research

                                      McKesson's (MCK) Specialty Health unit is likely to drive the company's top line in the third quarter of fiscal 2018.

                                        Zacks Equity Research

                                        What's in Store for Becton, Dickinson (BDX) in Q1 Earnings?

                                        by Zacks Equity Research

                                        Despite solid prospects in the emerging markets, Becton, Dickinson (BDX) is likely to witness sluggishness in BD Medical and BD Life Sciences in Q1.

                                          Zacks Equity Research

                                          Abbott (ABT) Tops Q4 Earnings and Revenues, Issues Guidance

                                          by Zacks Equity Research

                                          Abbott (ABT) posts promising Q4 results on strong growth in all lines and expansion in emerging markets.

                                            Zacks Equity Research

                                            Accuray (ARAY) Q2 Loss Narrower Than Estimates, Revenues Top

                                            by Zacks Equity Research

                                            Radixact System and major software overhaul drive Accuray (ARAY) in Q2.

                                              Zacks Equity Research

                                              Strength Seen in ResMed (RMD): Stock Soars 14.7%

                                              by Zacks Equity Research

                                              ResMed (RMD) was a big mover last session, as the company saw its shares rise more than 14% on the day amid huge volumes.

                                                Zacks Equity Research

                                                What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?

                                                by Zacks Equity Research

                                                Pacific Biosciences (PACB) is likely to witness year-over-year decline in product revenues.

                                                  Zacks Equity Research

                                                  AngioDynamics (ANGO) Banks on Buyouts, Debt Level High

                                                  by Zacks Equity Research

                                                  AngioDynamics (ANGO) continues to expand its business on the back of acquisitions and strategic alliances.